

Giampaolo Tortora

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11558356/publications.pdf>

Version: 2024-02-01

81
papers

16,736
citations

87723

38
h-index

71532

76
g-index

83
all docs

83
docs citations

83
times ranked

23617
citing authors

#	ARTICLE	IF	CITATIONS
1	Genomic analyses identify molecular subtypes of pancreatic cancer. <i>Nature</i> , 2016, 531, 47-52.	13.7	2,700
2	Whole genomes redefine the mutational landscape of pancreatic cancer. <i>Nature</i> , 2015, 518, 495-501.	13.7	2,132
3	EGFR Antagonists in Cancer Treatment. <i>New England Journal of Medicine</i> , 2008, 358, 1160-1174.	13.9	1,869
4	Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. <i>Nature</i> , 2012, 491, 399-405.	13.7	1,741
5	Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 317-327.	13.9	1,521
6	Whole-genome landscape of pancreatic neuroendocrine tumours. <i>Nature</i> , 2017, 543, 65-71.	13.7	716
7	Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy. <i>JAMA Oncology</i> , 2018, 4, 1543.	3.4	567
8	Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. <i>Nature Genetics</i> , 2013, 45, 1470-1473.	9.4	564
9	ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. <i>Cancer Research</i> , 2002, 62, 7284-90.	0.4	463
10	Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers. <i>PLoS ONE</i> , 2015, 10, e0130142.	1.1	390
11	Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. <i>Clinical Cancer Research</i> , 2002, 8, 3438-44.	3.2	343
12	Antitumor Activity of ZD6474, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Human Cancer Cells with Acquired Resistance to Anti-epidermal Growth Factor Receptor Therapy. <i>Clinical Cancer Research</i> , 2004, 10, 784-793.	3.2	337
13	A Meta-Analysis on the Interaction between HER-2 Expression and Response to Endocrine Treatment in Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 4741-4748.	3.2	312
14	Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. <i>Clinical Cancer Research</i> , 2003, 9, 1546-56.	3.2	263
15	First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non-Small-Cell Lung Cancer: The TORCH Randomized Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 3002-3011.	0.8	229
16	Hypermutation In Pancreatic Cancer. <i>Gastroenterology</i> , 2017, 152, 68-74.e2.	0.6	174
17	Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups. <i>Oncotarget</i> , 2014, 5, 2839-2852.	0.8	171
18	Vascular Endothelial Growth Factor Receptor-1 Contributes to Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Cancer Cells. <i>Clinical Cancer Research</i> , 2008, 14, 5069-5080.	3.2	139

#	ARTICLE	IF	CITATIONS
19	Key cancer cell signal transduction pathways as therapeutic targets. <i>European Journal of Cancer</i> , 2006, 42, 290-294.	1.3	131
20	Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications. <i>Nature Clinical Practice Oncology</i> , 2008, 5, 521-530.	4.3	107
21	Novel Toll-Like Receptor 9 Agonist Induces Epidermal Growth Factor Receptor (EGFR) Inhibition and Synergistic Antitumor Activity with EGFR Inhibitors. <i>Clinical Cancer Research</i> , 2006, 12, 577-583.	3.2	86
22	Cooperative Antitumor Effect of Multitargeted Kinase Inhibitor ZD6474 and Ionizing Radiation in Glioblastoma. <i>Clinical Cancer Research</i> , 2005, 11, 5639-5644.	3.2	83
23	Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy. <i>Frontiers in Pharmacology</i> , 2013, 4, 56.	1.6	79
24	Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies. <i>Drug Resistance Updates</i> , 2007, 10, 81-100.	6.5	74
25	Gene Expression Profiling of Lung Atypical Carcinoids and Large Cell Neuroendocrine Carcinomas Identifies Three Transcriptomic Subtypes with Specific Genomic Alterations. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1651-1661.	0.5	73
26	Angiogenesis: A Target for Cancer Therapy. <i>Current Pharmaceutical Design</i> , 2004, 10, 11-26.	0.9	72
27	Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy. <i>Differentiation</i> , 2007, 75, 788-799.	1.0	72
28	Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 3929-3939.	0.8	66
29	Combined Targeting of Endothelin A Receptor and Epidermal Growth Factor Receptor in Ovarian Cancer Shows Enhanced Antitumor Activity. <i>Cancer Research</i> , 2007, 67, 6351-6359.	0.4	65
30	TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 12468-12473.	3.3	63
31	Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases. <i>Journal of Cellular Physiology</i> , 2006, 208, 344-353.	2.0	59
32	The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells. <i>Endocrine-Related Cancer</i> , 2010, 18, 1-11.	1.6	58
33	Do immune checkpoint inhibitors need new studies methodology?. <i>Journal of Thoracic Disease</i> , 2018, 10, S1564-S1580.	0.6	58
34	The use of xenograft models for the selection of cancer treatments with the EGFR as an example. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 65, 200-211.	2.0	56
35	Involvement of Growth Factor Receptors of the Epidermal Growth Factor Receptor Family in Prostate Cancer Development and Progression to Androgen Independence. <i>Clinical Prostate Cancer</i> , 2003, 2, 50-57.	2.1	55
36	Toll-like Receptor 9 Agonist IMO Cooperates with Cetuximab in <i>K-Ras</i> Mutant Colorectal and Pancreatic Cancers. <i>Clinical Cancer Research</i> , 2011, 17, 6531-6541.	3.2	47

#	ARTICLE	IF	CITATIONS
37	Down-regulation of $\text{p}115$ subunit of camp-dependent protein kinase induces growth inhibition of human mammary epithelial cells transformed by c-ha-ras and c-erbB-2 proto-oncogenes. <i>International Journal of Cancer</i> , 1993, 53, 438-443.	2.3	46
38	Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting. <i>Oncologist</i> , 2016, 21, 283-291.	1.9	45
39	Genetic alterations analysis in prognostic stratified groups identified TP53 and ARID1A as poor clinical performance markers in intrahepatic cholangiocarcinoma. <i>Scientific Reports</i> , 2018, 8, 7119.	1.6	39
40	Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer. <i>Mediators of Inflammation</i> , 2019, 2019, 1-10.	1.4	39
41	Antisense strategies targeting protein kinase C: preclinical and clinical development. <i>Seminars in Oncology</i> , 2003, 30, 26-31.	0.8	35
42	A Novel Toll-Like Receptor 9 Agonist Cooperates with Trastuzumab in Trastuzumab-Resistant Breast Tumors through Multiple Mechanisms of Action. <i>Clinical Cancer Research</i> , 2009, 15, 6921-6930.	3.2	35
43	Reporting Tumor Molecular Heterogeneity in Histopathological Diagnosis. <i>PLoS ONE</i> , 2014, 9, e104979.	1.1	35
44	High mobility group A1 protein expression reduces the sensitivity of colon and thyroid cancer cells to antineoplastic drugs. <i>BMC Cancer</i> , 2014, 14, 851.	1.1	34
45	Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells. <i>Journal of Cellular Physiology</i> , 2008, 216, 698-707.	2.0	33
46	Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer. <i>Endocrine-Related Cancer</i> , 2005, 12, 1051-1058.	1.6	31
47	Targeting the epidermal growth factor receptor in solid tumors: focus on safety. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 535-549.	1.0	30
48	Rationale and clinical use of multitargeting anticancer agents. <i>Current Opinion in Pharmacology</i> , 2013, 13, 536-542.	1.7	29
49	Immuno-evolution of mouse pancreatic organoid isografts from preinvasive to metastatic disease. <i>Scientific Reports</i> , 2019, 9, 12286.	1.6	27
50	Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicity. <i>Translational Lung Cancer Research</i> , 2015, 4, 721-7.	1.3	26
51	Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with anti-PD1 in pancreatic cancer. , 2021, 9, e002876.		25
52	Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 1055-1069.	1.5	24
53	EGFR-targeting agents in oncology. <i>Expert Opinion on Therapeutic Patents</i> , 2008, 18, 889-901.	2.4	23
54	Antisense Targeting Protein Kinase A Type I as a Drug for Integrated Strategies of Cancer Therapy. <i>Annals of the New York Academy of Sciences</i> , 2003, 1002, 236-243.	1.8	22

#	ARTICLE	IF	CITATIONS
55	Increased anaerobic metabolism is a distinctive signature in a colorectal cancer cellular model of resistance to anti-epidermal growth factor receptor antibody. <i>Proteomics</i> , 2013, 13, 866-877.	1.3	21
56	Neoadjuvant immunotherapy is reshaping cancer management across multiple tumour types: The future is now!. <i>European Journal of Cancer</i> , 2021, 152, 155-164.	1.3	21
57	Selective Disruption of Insulin-like Growth Factor-1 (IGF-1) Signaling via Phosphoinositide-dependent Kinase-1 Prevents the Protective Effect of IGF-1 on Human Cancer Cell Death. <i>Journal of Biological Chemistry</i> , 2010, 285, 6563-6572.	1.6	20
58	The development of PARP as a successful target for cancer therapy. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 161-175.	1.1	16
59	Intraductal Pancreatic Mucinous Neoplasms: A Tumor-Biology Based Approach for Risk Stratification. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6386.	1.8	15
60	True 3q Chromosomal Amplification in Squamous Cell Lung Carcinoma by FISH and aCGH Molecular Analysis: Impact on Targeted Drugs. <i>PLoS ONE</i> , 2012, 7, e49689.	1.1	12
61	Predictors of outcome for patients with lung adenocarcinoma carrying the epidermal growth factor receptor mutation receiving 1st-line tyrosine kinase inhibitors: Sensitivity and meta-regression analysis of randomized trials. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 90, 135-145.	2.0	12
62	In vitro expansion of human breast cancer epithelial and mesenchymal stromal cells: optimization of a coculture model for personalized therapy approaches. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 3091-3100.	1.9	10
63	Mechanisms of resistance to EGFR inhibitors. <i>Targeted Oncology</i> , 2007, 2, 31-37.	1.7	10
64	A Tribute to John Mendelsohn: A Pioneer in Targeted Cancer Therapy. <i>Cancer Research</i> , 2019, 79, 4315-4323.	0.4	9
65	PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination: a systematic review and meta-analysis. <i>Immunotherapy</i> , 2019, 11, 921-930.	1.0	8
66	Case Report: BAP1 Mutation and RAD21 Amplification as Predictive Biomarkers to PARP Inhibitor in Metastatic Intrahepatic Cholangiocarcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 567289.	1.3	8
67	Organoid-Transplant Model Systems to Study the Effects of Obesity on the Pancreatic Carcinogenesis in vivo. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 308.	1.8	8
68	Moving towards a customized approach for drug development: lessons from clinical trials with immune checkpoint inhibitors in lung cancer. <i>Translational Lung Cancer Research</i> , 2015, 4, 704-12.	1.3	8
69	Pancreatic Cancer Patient-Derived Organoid Platforms: A Clinical Tool to Study Cell- and Non-Cell-Autonomous Mechanisms of Treatment Response. <i>Frontiers in Medicine</i> , 2021, 8, 793144.	1.2	8
70	Adipocytes and Neutrophils Give a Helping Hand to Pancreatic Cancers. <i>Cancer Discovery</i> , 2016, 6, 821-823.	7.7	7
71	Advances towards the design and development of personalized non-small-cell lung cancer drug therapy. <i>Expert Opinion on Drug Discovery</i> , 2013, 8, 1381-1397.	2.5	6
72	Avoiding chemotherapy for advanced nononcogene addicted NSCLC overexpressing PD-L1: Rule or option?. <i>Seminars in Oncology</i> , 2018, 45, 176-180.	0.8	5

#	ARTICLE	IF	CITATIONS
73	Addition of erlotinib to fluoropyrimidine-oxaliplatin-based chemotherapy with or without bevacizumab: Two sequential phase I trials. <i>Experimental and Therapeutic Medicine</i> , 2011, 2, 449-455.	0.8	3
74	Fecal microbiota transplantation to improve efficacy of immune checkpoint inhibitors in renal cell carcinoma (TACITO trial).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS407-TPS407.	0.8	3
75	A Novel ATM Pathogenic Variant in an Italian Woman with Gallbladder Cancer. <i>Genes</i> , 2021, 12, 313.	1.0	2
76	Combination of Anti-EGFR Drugs and Other Molecular Targeted Agents as Anti-Cancer Strategy. <i>Current Cancer Therapy Reviews</i> , 2007, 3, 117-126.	0.2	0
77	Mechanisms of Intrinsic and Acquired Resistance to EGFR Inhibitors. <i>Current Cancer Therapy Reviews</i> , 2007, 3, 276-283.	0.2	0
78	EGFR-Directed Monoclonal Antibodies. , 2010, , 407-436.		0
79	Early primary tumor response in metastatic RCC patients treated with immune checkpoint inhibitors-based combinations.. <i>Journal of Clinical Oncology</i> , 2022, 40, 349-349.	0.8	0
80	Network analysis to determine association between immuno-related toxicities and immune soluble profile in patients treated with anti-â€œPD-1.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2553-2553.	0.8	0
81	The impact of the multidisciplinary team (MDT) in the management of colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2022, 40, e13641-e13641.	0.8	0